🇺🇸 177Lu-PSMA-617 in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Kidney Disease — 1 report (16.67%)
  2. Cytopenia — 1 report (16.67%)
  3. Diverticulitis — 1 report (16.67%)
  4. Erectile Dysfunction — 1 report (16.67%)
  5. Intestinal Perforation — 1 report (16.67%)
  6. Sepsis — 1 report (16.67%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is 177Lu-PSMA-617 approved in United States?

177Lu-PSMA-617 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for 177Lu-PSMA-617 in United States?

European Organisation for Research and Treatment of Cancer - EORTC is the originator. The local marketing authorisation holder may differ — check the official source linked above.